Trimethoprim-Sulfamethoxazole

Verify with FDA CVM →

13 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
1
Deaths Reported
770.0%
Death Rate

Active Ingredients

Trimethoprim-Sulfamethoxazole

Administration Routes

UnknownOral

Species Affected

Dog 12
Ferret 1

Most Affected Breeds

Retriever - Golden 4
Retriever - Labrador 1
Spitz - Dutch (Keeshond) 1
Schnauzer - Miniature 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Siberian Husky 1
Pit Bull 1
Crossbred Canine/dog 1
Mastiff 1
Unknown 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 4
Emesis 4
Frequent urination 4
Cystitis 4
Lack of efficacy (endoparasite) - tapeworm 4
Urinary tract infection 3
Decreased appetite 2
Blood in urine 2
Diarrhoea 2
Tarry or black stool (see also haemorrhagic diarrhoea) 2
Other abnormal test result NOS 2
Lack of efficacy - NOS 2

Outcome Breakdown

Outcome Unknown
6 (46.2%)
Recovered/Normal
5 (38.5%)
Euthanized
1 (7.7%)
Ongoing
1 (7.7%)

Data Summary

Metric Value
Total adverse event reports 13
Reports involving death 1
Case-fatality rate (reported events) 770.0%
Distinct species in reports 2
Distinct breeds in reports 10
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Trimethoprim-Sulfamethoxazole Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 13 adverse event reports referencing Trimethoprim-Sulfamethoxazole, including 1 reports in which the animal died — a 770.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Trimethoprim-Sulfamethoxazole. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Trimethoprim-Sulfamethoxazole reports are Dog (12 reports), Ferret (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Golden (4), Retriever - Labrador (1), Spitz - Dutch (Keeshond) (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Trimethoprim-Sulfamethoxazole are Lethargy (see also Central nervous system depression in 'Neurological') (4), Emesis (4), Frequent urination (4), Cystitis (4). Of the 13 reports with a coded outcome, Outcome Unknown is the leading category at 46.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Trimethoprim-Sulfamethoxazole.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial